# Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

> **NCT04481191** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 400 (actual)

## Conditions studied

- Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9

## Interventions

- **BIOLOGICAL:** RotaTeq (V260)
- **BIOLOGICAL:** IPV

## Key facts

- **NCT ID:** NCT04481191
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-25
- **Primary completion:** 2021-05-08
- **Final completion:** 2021-05-08
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2024-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04481191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04481191, "Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04481191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*